<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813201</url>
  </required_header>
  <id_info>
    <org_study_id>TIC-0911</org_study_id>
    <secondary_id>2009-016498-13</secondary_id>
    <nct_id>NCT01813201</nct_id>
  </id_info>
  <brief_title>Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects</brief_title>
  <acronym>TIC</acronym>
  <official_title>A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to determine whether intermittent administration of
      testosterone against placebo is associated with a reduction of mortality and heart failure
      hospitalizations at 1 year, in male patients with advanced heart failure and testosterone
      deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure (HF) represents one of the major social and health problems, for its high
      prevalence and its huge economic impact, as well as the elevated morbidity and mortality
      associated. In Spain, the estimated prevalence is 7% over 45 years old, and it increases
      until 18% over 75 years old. Currently, HF is the leading cause of hospital admission over 65
      years and the mortality for patients with symptomatic HF remains worse than the majority of
      cancers. The estimated minimum expenditure is 1.1% of total health care costs and 2% of
      specialized medical care. This accounts for a staggeringly large financial burden on the
      health care system.

      Chronic HF is a complex disease, whose progression involves multiple pathophysiological
      systems. It is well established the deleterious effect of activation of
      renin-angiotensin-aldosterone and sympathetic nervous systems. The blockage of these systems
      by beta-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor
      blockers (ARBs) and aldosterone antagonists has improved prognosis. However, in spite of
      these therapies, the prognosis of patients with chronic HF remains poor.

      During the HF progression to advanced stages, it has been shown an anabolic and metabolic
      deterioration, resulting in a predominance of catabolic processes. The deficiency of anabolic
      hormones correlates with greater severity of symptoms, activation of neuroendocrine and
      inflammatory systems, insulin resistance, metabolic impairment, exercise intolerance, anemia
      and cardiac cachexia. All these processes take part of the final progression of the HF
      disease until death, when HF becomes a systemic disease. In men with HF, levels of
      testosterone (the main anabolic hormone) are decreased; in fact, 30% of men have levels below
      the 10th percentile of a reference healthy population adjusted for age. The deterioration of
      anabolic hormones correlates inversely with the severity of HF disease and it determines a
      higher mortality. In fact, low testosterone levels are associated with reduced cardiac
      output, greater symptomatic limitation and higher mortality. Therefore, testosterone
      deficiency in men with HF has a detrimental impact on symptoms and prognosis.

      In addition, testosterone has shown to have beneficial effects on HF patients, such as
      vasodilatation of coronary and peripheral arteries, inotropic effects, reduction of
      neurohormonal activation, anti-inflammatory and immunomodulatory actions, reduction of
      cytokine production and improvement of muscle strength. All these actions have a potential
      benefit in patients with HF, because they are involved in the progression of the disease,
      especially at advanced stages.

      The rational approach &quot;testosterone replacement for improving the prognosis of patients with
      advanced HF and testosterone deficiency&quot; has strong pathophysiological plausibility. To date,
      no other clinical trials have evaluated the effect of testosterone replacement on morbidity
      and mortality.

      However, in the last years, numerous editorials in leading journals have concluded on the
      need to clarify the effect of testosterone therapy on cardiac function and the morbimortality
      in patients with advanced HF.

      Our group has worked in the last years in this field, confirming the presence of a
      testosterone deficiency in men with chronic HF, which is associated with a worse prognosis
      and a greater decline in exercise capacity.

      Therefore, the investigators propose a clinical trial of morbimortality in a population with
      advanced heart failure and associated deficiency on testosterone; in which, the previous
      background justifies the potential benefit of testosterone replacement therapy. In addition,
      the large clinical impact of this disease supports the priority need of an independent study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Death from any cause or hospitalization for heart failure or decompensation of heart failure requiring intravenous drug for stabilization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality from cardiovascular causes, for HF and other causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmissions for any reason.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of decompensated heart failure who have required intravenous medication for stabilization.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in test quality of life (Minnesota Living Heart Failure) and clinical modified Framingham score.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac function parameters assessed by echocardiography and natriuretic peptide (NT)-proBNP concentration.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Testosterone undecanoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline isotonic solution (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate</intervention_name>
    <description>Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).</description>
    <arm_group_label>Testosterone undecanoate</arm_group_label>
    <other_name>ReandronÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline isotonic solution</intervention_name>
    <description>Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)</description>
    <arm_group_label>Saline isotonic solution (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one hospital admission for HF.

          -  Stable clinical status, New York Heart Association (NYHA) functional class II-IV.

          -  Left ventricular ejection fraction of less than 40%

          -  NT-proBNP concentration greater than 1000 pg / ml.

          -  Total testosterone and free testosterone deficiency measured in the last month

          -  Age &gt;18 years.

          -  Patients who have given their written informed consent.

        Exclusion Criteria:

          -  No informed consent.

          -  Taking oral anticoagulants

          -  Severe valvular heart disease with an indication for surgical repair.

          -  Extracardiac disease with an estimated prognosis of less than 1 year.

          -  History of androgen-dependent prostate cancer, benign prostate hyperplasia treatment
             or prostate-specific antigen (PSA)&gt; 3 ng / ml.

          -  History of breast carcinoma or liver tumor

          -  Severe renal impairment (glomerular filtration rate &lt;30 ml / kg / min).

          -  Acute coronary syndrome in the last year

          -  Renal or hepatic failure

          -  Uncontrolled hypertension

          -  Erythrocytosis (hematocrit&gt; 5%)

          -  Hypersensitivity to testosterone or any excipients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domingo A Pascual-Figal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoni Bayes-Genis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Service, Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh/68006333</url>
    <description>MeSH Terms</description>
  </link>
  <link>
    <url>http://www.secardiologia.es/</url>
    <description>Spanish Cardiology Society</description>
  </link>
  <reference>
    <citation>RodrÃ­guez-Artalejo F, Banegas Banegas JR, Guallar-CastillÃ³n P. [Epidemiology of heart failure]. Rev Esp Cardiol. 2004 Feb;57(2):163-70. Review. Spanish.</citation>
    <PMID>14967113</PMID>
  </reference>
  <reference>
    <citation>Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.</citation>
    <PMID>15152059</PMID>
  </reference>
  <reference>
    <citation>Pugh PJ, English KM, Jones TH, Channer KS. Testosterone: a natural tonic for the failing heart? QJM. 2000 Oct;93(10):689-94. Review.</citation>
    <PMID>11029481</PMID>
  </reference>
  <reference>
    <citation>Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res. 2009;37:183-96. doi: 10.1159/000176053. Review.</citation>
    <PMID>19011297</PMID>
  </reference>
  <reference>
    <citation>Pugh PJ, Jones RD, Jones TH, Channer KS. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail. 2002 Dec;4(6):673-80. Review.</citation>
    <PMID>12453536</PMID>
  </reference>
  <reference>
    <citation>Anker SD, Al-Nasser FO. Chronic heart failure as a metabolic disorder. Heart Fail Monit. 2000;1(2):42-9. Review.</citation>
    <PMID>12634873</PMID>
  </reference>
  <reference>
    <citation>Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997 Jul 15;96(2):526-34.</citation>
    <PMID>9244221</PMID>
  </reference>
  <reference>
    <citation>Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, Tsagalou EP, Nanas JN. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003 Feb;87(2-3):179-83.</citation>
    <PMID>12559538</PMID>
  </reference>
  <reference>
    <citation>Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, Kawano H, Kugiyama K, Ogawa H, Saito Y, Nakao K. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab. 2000 May;85(5):1834-40.</citation>
    <PMID>10843161</PMID>
  </reference>
  <reference>
    <citation>Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006 Oct 24;114(17):1829-37. Epub 2006 Oct 9.</citation>
    <PMID>17030678</PMID>
  </reference>
  <reference>
    <citation>Jankowska EA, Filippatos G, Ponikowska B, Borodulin-Nadzieja L, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail. 2009 Jun;15(5):442-50. doi: 10.1016/j.cardfail.2008.12.011. Epub 2009 Feb 10.</citation>
    <PMID>19477405</PMID>
  </reference>
  <reference>
    <citation>P PeÃ±afiel, DA Pascual, B. Redondo, P Nicolas, PL Tornel, J Sanchez-Mas, G de la Morena, M ValdÃ©s. Anabolic deficiency as determinant of functional impairment and prognosis in heart failure patients. European journal of Heart Failure 2007;6(supl 1):146.</citation>
  </reference>
  <reference>
    <citation>Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003 May;24(10):909-15.</citation>
    <PMID>12714022</PMID>
  </reference>
  <reference>
    <citation>Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail. 2007 Jan;9(1):44-50. Epub 2006 Jul 7.</citation>
    <PMID>16828341</PMID>
  </reference>
  <reference>
    <citation>Rauchhaus M, Doehner W, Anker SD. Heart failure therapy: testosterone replacement and its implications. Eur Heart J. 2006 Jan;27(1):10-2. Epub 2005 Nov 16.</citation>
    <PMID>16291772</PMID>
  </reference>
  <reference>
    <citation>Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004 Apr;90(4):446-7.</citation>
    <PMID>15020527</PMID>
  </reference>
  <reference>
    <citation>Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006 Jan;27(1):57-64. Epub 2005 Aug 10.</citation>
    <PMID>16093267</PMID>
  </reference>
  <reference>
    <citation>Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 Sep 1;54(10):919-27. doi: 10.1016/j.jacc.2009.04.078.</citation>
    <PMID>19712802</PMID>
  </reference>
  <reference>
    <citation>Aukrust P, Ueland T, Gullestad L, Yndestad A. Testosterone: a novel therapeutic approach in chronic heart failure? J Am Coll Cardiol. 2009 Sep 1;54(10):928-9. doi: 10.1016/j.jacc.2009.05.039.</citation>
    <PMID>19712803</PMID>
  </reference>
  <reference>
    <citation>Pascual-Figal DA, Tornel PL, Valdes M. Letter by Pascual-Figal et al regarding article, &quot;Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival&quot;. Circulation. 2007 May 29;115(21):e548; author reply e549.</citation>
    <PMID>17533191</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Anabolic deterioration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

